Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Obstetrics and Gynecology
Volume 2017, Article ID 8458375, 6 pages
Case Report

Atypical Amniotic Fluid Embolism Managed with a Novel Therapeutic Regimen

1Department of Obstetrics and Gynecology, Kaiser Permanente Southern California, 1200 Discovery Drive, Bakersfield, Kern County, CA 93309, USA
2School of Medicine, St. George’s University, St. George’s, Grenada
3Department of Anesthesiology, Adventist Health Bakersfield, 2615 Chester Avenue, Bakersfield, CA 93301, USA
4Department of Obstetrics and Gynecology, Lincoln Medical and Mental Health Center, 234 East 149th Street, Bronx, NY 10451, USA

Correspondence should be addressed to Shadi Rezai; ude.ugs@ahszer and Cassandra E. Henderson; gro.chhcyn@nosredneh.ardnassac

Received 16 July 2017; Revised 26 September 2017; Accepted 19 November 2017; Published 21 December 2017

Academic Editor: Edi Vaisbuch

Copyright © 2017 Shadi Rezai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Amniotic fluid embolism (AFE) is the second leading cause of maternal mortality in the USA with an incidence of 1 : 15,200 births. The case fatality rate and perinatal mortality associated with AFE are 13–30% and 9–44%, respectively. This rare but devastating complication can be difficult to diagnose as many of the early signs and symptoms are nonspecific. Compounding this diagnostic challenge is a lack of effective treatment regimens which to date are mostly supportive. We present the case of a 26-year-old woman who suffered from suspected AFE and was successfully treated with the novel regimen of Atropine, Ondansetron, and Ketorolac (A-OK). The authors acknowledge that this case does not meet the new criteria proposed, by Clark in 2016, but feel that it is important to share this case report, due to dramatic patient response to the provided supportive therapy presented in this case report. We hope this case report will prompt further research into this novel approach to treating AFE with Atropine, Ondansetron, and Ketorolac.